Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia

Haematologica

Volumn 88, Issue 2, 2003, Pages 229-230

  Oriol, Albert ^a   Ribera, Josep Maria ^b   Brunet, Salut ^b   Esteve, Jordi ^b   Bueno, Javier ^b   Llorente, Andrés ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

Acute myeloid leukemia; Elderly patients; Oral chemotherapy; Survival

Indexed keywords

ETOPOSIDE; IDARUBICIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; RESPIRATORY TRACT DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; ACUTE DISEASE; LETTER; MORTALITY; MYELOID LEUKEMIA; ORAL DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037608688     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Veneri D, Zanetti F, Franchini M, Ambrosetti A, Pizzolo G. Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients. Haematologica 2002;87:447-8.
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
3. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
4. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Bruno A, et al. Biological features of acute myeloid leukemia in the elderly. Blood 1998;92:697-9.
5. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-11.
6. Kahn SB, Ebrahim K, Cassileth P, Bennett JM, Knospe WH, O'Connell MJ. Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot Study. Am J Clin Oncol 1989;12:201-4.
7. Ruutu T, Elonen E. Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia. Hematol Oncol 1991;9:87-92.
8. Ruutu T, Almqvist A, Hallman H, Honkanen T, Jarvenpaa E, Jarventie G, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia 1994;8:11-5.
9. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press;2001.